BVXV's logo.
Ticker Symbol: BVXV

Biondvax Pharmaceuticals Ltd - ADR

$2.16 - 21-07-2024 4 p.m. ET

Exchange: NASDAQ Country: Israel Currency: USD Asset Type: ADR CIK:0001611747

Company Profile

BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company focused on development and manufacturing of products for the prevention of infectious diseases. The Company had been developing M 001, a novel flu vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of flu strains. In October 2020, the Company completed a Phase 3 clinical trial of M 001 which failed to meet the trial’s primary and secondary efficacy endpoints. The company is now pursuing opportunities in the infectious disease space, including exploring several alternatives for development of a pipeline of assets.

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: Weizmann Science Park
CEO: Ron Babecoff
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing


Last Updated: December 31, 1969 07:00 PM EST
Previous Close: -
Change: - ( 0.00%)
Days Range: $1.32 - $1.37
Beta: 0.42
52wk. High: $11.49
52wk. Low: $0.53
Ytd. Change -54.05%
50 Day Moving Average: $1.34
200 Day Moving Average: $1.71
Shares Outstanding: 653549


Market Cap: 88.9M
PE Ratio: -
EPS (TTM): 0


Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A